Highlights Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Market Closed - OTC Markets Other stock markets 15:47:36 2024-05-15 EDT			5-day change	1st Jan Change
2.76 ^USD	+3.37%		+8.24%	+217.24%

05-10	Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-01	Kiromic BioPharma, Inc. announced that it has received $2 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	04-24	CI
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	04-02	CI
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial	03-19	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	02-14	CI
Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer	01-29	CI
Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial	01-05	CI
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel? for the Treatment of Non-Small Cell Lung Cancer	12-14	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Kiromic Biopharma, Inc. Announces Deltacel?? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center	11-09	CI
Kiromic BioPharma, Inc. and Beverly Hills Cancer Center Enter Clinical Trial Agreement	23-10-23	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer	23-05-01	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Kiromic Biopharma, Inc. Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer	23-04-03	CI
Kiromic BioPharma Announces 1-for-30 Reverse Stock Split	23-03-10	MT
Kiromic BioPharma, Inc. Reports Favorable Deltacel Preclinical Pharmacology Results	23-02-28	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Highlights

Filters